Imhoff John E

SEC source: 0001477932-26-002052 · form4.xml · derivative · entry 6

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,000

Underlying: Common Stock · 156,086 shares

Expires 2027-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: On March 31, 2026, Dr. Imhoff converted $11,019.18 outstanding under a September 25, 2025 Convertible Promissory Note into 157,417 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $1,019.18 of accrued interest. Following the reported conversion, $110,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.

F4 · shares: On March 31, 2026, Dr. Imhoff converted $11,019.18 outstanding under a September 25, 2025 Convertible Promissory Note into 157,417 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $1,019.18 of accrued interest. Following the reported conversion, $110,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.

F4 · derivative.underlying_shares: On March 31, 2026, Dr. Imhoff converted $11,019.18 outstanding under a September 25, 2025 Convertible Promissory Note into 157,417 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $1,019.18 of accrued interest. Following the reported conversion, $110,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.

SEC source: 0001477932-26-002052 · form4.xml · nonDerivative · entry 4

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,252,673

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: On March 31, 2026, Dr. Imhoff converted $11,019.18 outstanding under a September 25, 2025 Convertible Promissory Note into 157,417 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $1,019.18 of accrued interest. Following the reported conversion, $110,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.

SEC source: 0001477932-26-002052 · form4.xml · nonDerivative · entry 3

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,095,256

F3 · kind: On March 26, 2026, Mr. Imhoff converted 10 shares of Series F preferred stock into 40,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price.

F3 · price: On March 26, 2026, Mr. Imhoff converted 10 shares of Series F preferred stock into 40,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price.

SEC source: 0001477932-26-002052 · form4.xml · nonDerivative · entry 2

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F3 · kind: On March 26, 2026, Mr. Imhoff converted 10 shares of Series F preferred stock into 40,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price.

F3 · price: On March 26, 2026, Mr. Imhoff converted 10 shares of Series F preferred stock into 40,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price.

SEC source: 0001477932-26-002052 · form4.xml · nonDerivative · entry 1

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,055,256

F2 · kind: These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.2773.

F2 · price: These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.2773.

SEC source: 0001477932-26-002052 · form4.xml · derivative · entry 5

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,000

Underlying: Common Stock · 110,000 shares

Expires 2036-03-09

F1 · derivative.exercise_date: One-fourth of the shares subject to the award vested on March 10, 2026; the remaining shares will vest monthly, starting on June 10, 2026, subject to the reporting person's continued service on each such date, until the award is fully vested on March 10, 2029.

SEC source: 0001477932-26-001320 · form4.xml · derivative · entry 15

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 156,086 shares

Expires 2027-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · kind: On February 26, 2026, Dr. Imhoff converted $10,926.03 outstanding under a September 25, 2025 Convertible Promissory Note into 156,086 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $926.03 of accrued interest. Following the reported conversion, $120,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.

F6 · shares: On February 26, 2026, Dr. Imhoff converted $10,926.03 outstanding under a September 25, 2025 Convertible Promissory Note into 156,086 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $926.03 of accrued interest. Following the reported conversion, $120,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.

F6 · price: On February 26, 2026, Dr. Imhoff converted $10,926.03 outstanding under a September 25, 2025 Convertible Promissory Note into 156,086 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $926.03 of accrued interest. Following the reported conversion, $120,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.

F6 · derivative.underlying_shares: On February 26, 2026, Dr. Imhoff converted $10,926.03 outstanding under a September 25, 2025 Convertible Promissory Note into 156,086 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $926.03 of accrued interest. Following the reported conversion, $120,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.

F6 · balance_after: On February 26, 2026, Dr. Imhoff converted $10,926.03 outstanding under a September 25, 2025 Convertible Promissory Note into 156,086 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $926.03 of accrued interest. Following the reported conversion, $120,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.

SEC source: 0001477932-26-001320 · form4.xml · nonDerivative · entry 7

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,053,099

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · kind: On February 26, 2026, Dr. Imhoff converted $10,926.03 outstanding under a September 25, 2025 Convertible Promissory Note into 156,086 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $926.03 of accrued interest. Following the reported conversion, $120,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.

SEC source: 0001477932-26-001320 · form4.xml · nonDerivative · entry 6

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,897,013

F5 · kind: On February 27, 2026, Mr. Imhoff converted 100 shares of Series E preferred stock into 400,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price.

F5 · price: On February 27, 2026, Mr. Imhoff converted 100 shares of Series E preferred stock into 400,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price.

SEC source: 0001477932-26-001320 · form4.xml · nonDerivative · entry 5

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F5 · kind: On February 27, 2026, Mr. Imhoff converted 100 shares of Series E preferred stock into 400,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price.

F5 · price: On February 27, 2026, Mr. Imhoff converted 100 shares of Series E preferred stock into 400,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price.

SEC source: 0001477932-26-001320 · form4.xml · derivative · entry 14

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 500,000 shares

Expires 2026-02-25

F4 · price: During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027.

SEC source: 0001477932-26-001320 · form4.xml · derivative · entry 13

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2026-02-25

F4 · kind: During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027.

F4 · price: During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027.

SEC source: 0001477932-26-001320 · form4.xml · derivative · entry 12

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 500,000 shares

Expires 2026-09-01

F4 · kind: During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027.

F4 · price: During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027.

SEC source: 0001477932-26-001320 · form4.xml · derivative · entry 11

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2027-09-01

F4 · kind: During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027.

F4 · price: During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027.

SEC source: 0001477932-26-001320 · form4.xml · derivative · entry 10

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 500,000 shares

Expires 2026-09-01

F4 · kind: During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027.

F4 · price: During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027.

SEC source: 0001477932-26-001320 · form4.xml · nonDerivative · entry 4

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,497,013

F4 · price: During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027.

SEC source: 0001477932-26-001320 · form4.xml · derivative · entry 9

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Common Stock · 312,720 shares

Expires 2027-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: On February 2, 2026, Dr. Imhoff converted $21,890.41 outstanding under a September 25, 2025 Convertible Promissory Note into 312,720 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $20,000 of principal and $1,890.41 of accrued interest. Following the reported conversion, $130,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.

F3 · shares: On February 2, 2026, Dr. Imhoff converted $21,890.41 outstanding under a September 25, 2025 Convertible Promissory Note into 312,720 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $20,000 of principal and $1,890.41 of accrued interest. Following the reported conversion, $130,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.

F3 · price: On February 2, 2026, Dr. Imhoff converted $21,890.41 outstanding under a September 25, 2025 Convertible Promissory Note into 312,720 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $20,000 of principal and $1,890.41 of accrued interest. Following the reported conversion, $130,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.

F3 · derivative.underlying_shares: On February 2, 2026, Dr. Imhoff converted $21,890.41 outstanding under a September 25, 2025 Convertible Promissory Note into 312,720 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $20,000 of principal and $1,890.41 of accrued interest. Following the reported conversion, $130,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.

F3 · balance_after: On February 2, 2026, Dr. Imhoff converted $21,890.41 outstanding under a September 25, 2025 Convertible Promissory Note into 312,720 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $20,000 of principal and $1,890.41 of accrued interest. Following the reported conversion, $130,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.

SEC source: 0001477932-26-001320 · form4.xml · nonDerivative · entry 3

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,997,013

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: On February 2, 2026, Dr. Imhoff converted $21,890.41 outstanding under a September 25, 2025 Convertible Promissory Note into 312,720 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $20,000 of principal and $1,890.41 of accrued interest. Following the reported conversion, $130,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.

SEC source: 0001477932-26-001320 · form4.xml · nonDerivative · entry 2

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,684,293

F2 · kind: These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.3157.

F2 · price: These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.3157.

SEC source: 0001477932-26-001320 · form4.xml · derivative · entry 8

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 195,460 shares

Expires 2027-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On December 18, 2025, Dr. Imhoff converted $13,682.19 outstanding under a September 25, 2025 Convertible Promissory Note into 195,460 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $3,682.19 of accrued interest. Following the reported conversion, $150,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.

F1 · shares: On December 18, 2025, Dr. Imhoff converted $13,682.19 outstanding under a September 25, 2025 Convertible Promissory Note into 195,460 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $3,682.19 of accrued interest. Following the reported conversion, $150,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.

F1 · price: On December 18, 2025, Dr. Imhoff converted $13,682.19 outstanding under a September 25, 2025 Convertible Promissory Note into 195,460 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $3,682.19 of accrued interest. Following the reported conversion, $150,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.

F1 · derivative.underlying_shares: On December 18, 2025, Dr. Imhoff converted $13,682.19 outstanding under a September 25, 2025 Convertible Promissory Note into 195,460 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $3,682.19 of accrued interest. Following the reported conversion, $150,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.

F1 · balance_after: On December 18, 2025, Dr. Imhoff converted $13,682.19 outstanding under a September 25, 2025 Convertible Promissory Note into 195,460 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $3,682.19 of accrued interest. Following the reported conversion, $150,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.

SEC source: 0001477932-26-001320 · form4.xml · nonDerivative · entry 1

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,658,955

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On December 18, 2025, Dr. Imhoff converted $13,682.19 outstanding under a September 25, 2025 Convertible Promissory Note into 195,460 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $3,682.19 of accrued interest. Following the reported conversion, $150,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.

SEC source: 0001477932-25-006528 · form4.xml · derivative · entry 5

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 191,667

Underlying: Common Stock · 166,667 shares

Expires 2029-08-29

F3 · kind: On August 29, 2025, the Company entered into a Securities Purchase Agreement with Dr. Imhoff, pursuant to which the Company agreed to sell, for a total price of $30,000, 166,667 units, each unit consisting of one share of common stock and one warrant to purchase up to 166,667 shares of common stock (the "August Warrants"). The August Warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.25 per share.

F3 · price: On August 29, 2025, the Company entered into a Securities Purchase Agreement with Dr. Imhoff, pursuant to which the Company agreed to sell, for a total price of $30,000, 166,667 units, each unit consisting of one share of common stock and one warrant to purchase up to 166,667 shares of common stock (the "August Warrants"). The August Warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.25 per share.

SEC source: 0001477932-25-006528 · form4.xml · nonDerivative · entry 4

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,463,495

F3 · kind: On August 29, 2025, the Company entered into a Securities Purchase Agreement with Dr. Imhoff, pursuant to which the Company agreed to sell, for a total price of $30,000, 166,667 units, each unit consisting of one share of common stock and one warrant to purchase up to 166,667 shares of common stock (the "August Warrants"). The August Warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.25 per share.

SEC source: 0001477932-25-006528 · form4.xml · nonDerivative · entry 3

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,296,828

F2 · kind: On August 21, 2025, Mr. Imhoff converted 300 shares of Series E preferred stock into 1,200,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price.

F2 · price: On August 21, 2025, Mr. Imhoff converted 300 shares of Series E preferred stock into 1,200,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price.

SEC source: 0001477932-25-006528 · form4.xml · nonDerivative · entry 2

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100

F2 · kind: On August 21, 2025, Mr. Imhoff converted 300 shares of Series E preferred stock into 1,200,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price.

F2 · price: On August 21, 2025, Mr. Imhoff converted 300 shares of Series E preferred stock into 1,200,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price.

SEC source: 0001477932-25-006528 · form4.xml · nonDerivative · entry 1

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,096,828

F1 · kind: These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.2298.

F1 · price: These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.2298.

SEC source: 0001477932-25-004559 · form4.xml · derivative · entry 1

Imhoff John E · CIK 0001348439 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,000

Underlying: Common Stock · 110,000 shares

Expires 2035-06-02

F1 · derivative.exercise_date: One-fourth of the shares subject to the award vested on June 3, 2025; the remaining shares will vest monthly, starting on September 3, 2025, subject to the reporting person's continued service on each such date, until the award is fully vested on June 2, 2028.

SEC source: 0001477932-25-002818 · form4.xml · nonDerivative · entry 10

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,992,380

F6 · kind: These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943.

F6 · price: These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943.

SEC source: 0001477932-25-004137 · form4a.xml · nonDerivative · entry 11

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,992,380

F7 · kind: These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943.

F7 · price: These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943.

SEC source: 0001477932-25-002818 · form4.xml · derivative · entry 12

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,263,069

Underlying: Common Stock · 263,069 shares

Expires 2029-03-17

F5 · kind: In connection with the March Purchase Agreement, the Company entered into an exchange agreement with Dr. Imhoff, whereby Dr. Imhoff agreed to exchange a $25,000 note payable and accrued interest of $1,307 for 263,069 units as described above.

F5 · price: In connection with the March Purchase Agreement, the Company entered into an exchange agreement with Dr. Imhoff, whereby Dr. Imhoff agreed to exchange a $25,000 note payable and accrued interest of $1,307 for 263,069 units as described above.

SEC source: 0001477932-25-002818 · form4.xml · derivative · entry 11

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,000,000

Underlying: Common Stock · 1,000,000 shares

Expires 2029-03-17

F4 · kind: On March 18, 2025, the Company entered into a Securities Purchase Agreement (the "March Purchase Agreement") with Dr. Imhoff, pursuant to which the Company agreed to sell, for a total price of $100,000, 1,000,000 units, each unit consisting of one share of common stock and one warrant to purchase up to 1,000,000 shares of common stock (the "March Warrants"). The March Warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.13 per share.

F4 · price: On March 18, 2025, the Company entered into a Securities Purchase Agreement (the "March Purchase Agreement") with Dr. Imhoff, pursuant to which the Company agreed to sell, for a total price of $100,000, 1,000,000 units, each unit consisting of one share of common stock and one warrant to purchase up to 1,000,000 shares of common stock (the "March Warrants"). The March Warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.13 per share.

SEC source: 0001477932-25-002818 · form4.xml · nonDerivative · entry 9

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,986,015

F5 · kind: In connection with the March Purchase Agreement, the Company entered into an exchange agreement with Dr. Imhoff, whereby Dr. Imhoff agreed to exchange a $25,000 note payable and accrued interest of $1,307 for 263,069 units as described above.

SEC source: 0001477932-25-002818 · form4.xml · nonDerivative · entry 8

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,722,946

F4 · kind: On March 18, 2025, the Company entered into a Securities Purchase Agreement (the "March Purchase Agreement") with Dr. Imhoff, pursuant to which the Company agreed to sell, for a total price of $100,000, 1,000,000 units, each unit consisting of one share of common stock and one warrant to purchase up to 1,000,000 shares of common stock (the "March Warrants"). The March Warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.13 per share.

SEC source: 0001477932-25-004137 · form4a.xml · derivative · entry 13

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,263,069

Underlying: Common Stock · 263,069 shares

Expires 2029-03-17

F6 · kind: These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943.

F6 · price: These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943.

SEC source: 0001477932-25-004137 · form4a.xml · derivative · entry 12

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,000,000

Underlying: Common Stock · 1,000,000 shares

Expires 2029-03-17

F5 · kind: In connection with the March Purchase Agreement, the Company entered into an exchange agreement with Dr. Imhoff, whereby Dr. Imhoff agreed to exchange a $25,000 note payable and accrued interest of $1,307 for 263,069 units as described above.

F5 · price: In connection with the March Purchase Agreement, the Company entered into an exchange agreement with Dr. Imhoff, whereby Dr. Imhoff agreed to exchange a $25,000 note payable and accrued interest of $1,307 for 263,069 units as described above.

SEC source: 0001477932-25-004137 · form4a.xml · nonDerivative · entry 10

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,986,015

F6 · kind: These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943.

SEC source: 0001477932-25-004137 · form4a.xml · nonDerivative · entry 9

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,722,946

F5 · kind: In connection with the March Purchase Agreement, the Company entered into an exchange agreement with Dr. Imhoff, whereby Dr. Imhoff agreed to exchange a $25,000 note payable and accrued interest of $1,307 for 263,069 units as described above.

SEC source: 0001477932-25-004137 · form4a.xml · nonDerivative · entry 8

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 400

F4 · kind: On March 13, 2025, for a purchase price of $30,000, Mr. Imhoff purchased 150 shares of Series E preferred stock from a third party. The shares have a conversion price of $0.25 and a stated value of $1,000.

F4 · price: On March 13, 2025, for a purchase price of $30,000, Mr. Imhoff purchased 150 shares of Series E preferred stock from a third party. The shares have a conversion price of $0.25 and a stated value of $1,000.

SEC source: 0001477932-25-002818 · form4.xml · nonDerivative · entry 7

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,722,946

F3 · kind: On March 7, 2025, for a purchase price of $112,934.50, Mr. Imhoff purchased 286 shares of Series C preferred stock from a third party. The shares had a conversion price of $0.1266, and on March 11, 2025 were converted to 2,258,690 common shares.

SEC source: 0001477932-25-002818 · form4.xml · nonDerivative · entry 6

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F3 · kind: On March 7, 2025, for a purchase price of $112,934.50, Mr. Imhoff purchased 286 shares of Series C preferred stock from a third party. The shares had a conversion price of $0.1266, and on March 11, 2025 were converted to 2,258,690 common shares.

F3 · price: On March 7, 2025, for a purchase price of $112,934.50, Mr. Imhoff purchased 286 shares of Series C preferred stock from a third party. The shares had a conversion price of $0.1266, and on March 11, 2025 were converted to 2,258,690 common shares.

SEC source: 0001477932-25-004137 · form4a.xml · nonDerivative · entry 7

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,722,946

SEC source: 0001477932-25-004137 · form4a.xml · nonDerivative · entry 6

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F3 · price: On March 7, 2025, for a purchase price of $112,934.50, Mr. Imhoff purchased 286 shares of Series C preferred stock from a third party. The shares had a conversion price of $0.1266, and on March 11, 2025 were converted to 2,258,690 common shares.

SEC source: 0001477932-25-002818 · form4.xml · nonDerivative · entry 5

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 286

F3 · kind: On March 7, 2025, for a purchase price of $112,934.50, Mr. Imhoff purchased 286 shares of Series C preferred stock from a third party. The shares had a conversion price of $0.1266, and on March 11, 2025 were converted to 2,258,690 common shares.

F3 · price: On March 7, 2025, for a purchase price of $112,934.50, Mr. Imhoff purchased 286 shares of Series C preferred stock from a third party. The shares had a conversion price of $0.1266, and on March 11, 2025 were converted to 2,258,690 common shares.

SEC source: 0001477932-25-004137 · form4a.xml · nonDerivative · entry 5

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 286

F3 · price: On March 7, 2025, for a purchase price of $112,934.50, Mr. Imhoff purchased 286 shares of Series C preferred stock from a third party. The shares had a conversion price of $0.1266, and on March 11, 2025 were converted to 2,258,690 common shares.

SEC source: 0001477932-25-002818 · form4.xml · nonDerivative · entry 4

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,464,256

F2 · kind: On March 6, 2025, Mr. Imhoff signed an exchange agreement to convert shares of Series C2 preferred stock at $0.50 conversion prices. For 2,400.75 Series C2 preferred shares, Mr. Imhoff received 4,801,500 common shares.

SEC source: 0001477932-25-002818 · form4.xml · nonDerivative · entry 3

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F2 · kind: On March 6, 2025, Mr. Imhoff signed an exchange agreement to convert shares of Series C2 preferred stock at $0.50 conversion prices. For 2,400.75 Series C2 preferred shares, Mr. Imhoff received 4,801,500 common shares.

F2 · price: On March 6, 2025, Mr. Imhoff signed an exchange agreement to convert shares of Series C2 preferred stock at $0.50 conversion prices. For 2,400.75 Series C2 preferred shares, Mr. Imhoff received 4,801,500 common shares.

SEC source: 0001477932-25-002818 · form4.xml · nonDerivative · entry 2

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,662,756

F1 · kind: On March 6, 2025, Mr. Imhoff converted 300 shares of Series D preferred stock into 900,000 shares of common stock. The Series D preferred stock had a stated value of $750 and $0.25 exercise price.

F1 · price: On March 6, 2025, Mr. Imhoff converted 300 shares of Series D preferred stock into 900,000 shares of common stock. The Series D preferred stock had a stated value of $750 and $0.25 exercise price.

SEC source: 0001477932-25-002818 · form4.xml · nonDerivative · entry 1

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: On March 6, 2025, Mr. Imhoff converted 300 shares of Series D preferred stock into 900,000 shares of common stock. The Series D preferred stock had a stated value of $750 and $0.25 exercise price.

F1 · price: On March 6, 2025, Mr. Imhoff converted 300 shares of Series D preferred stock into 900,000 shares of common stock. The Series D preferred stock had a stated value of $750 and $0.25 exercise price.

SEC source: 0001477932-25-004137 · form4a.xml · nonDerivative · entry 4

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,464,256

SEC source: 0001477932-25-004137 · form4a.xml · nonDerivative · entry 3

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F2 · price: On March 6, 2025, Mr. Imhoff signed an exchange agreement to convert shares of Series C2 preferred stock at $0.50 conversion prices. For 2,400.75 Series C2 preferred shares, Mr. Imhoff received 4,801,500 common shares.